MYH14 and central nervous system cancer: We further showed the enhanced effectiveness of BNCT by interrupting the myosin contractility with a Food and Drug Administration (FDA)-approved reagent Y-27632, as well as the potential of Y-27632 as adjuvant therapy for BNCT treatment of glioma.